A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients

被引：0
|
作者：
Ibrahim, Ahmed [1 ]
Yousaf, Muhammad Abdullah [1 ]
Anwar, Zain [2 ]
Anum [3 ]
Batool, Maha [1 ]
Rehman, Mohammad [1 ]
Safdar, Omar A. [4 ]
Khattak, Zeeshan Ahmed [5 ]
Faraz, Fatima [1 ]
Khalid, Huma [1 ]
机构：
[1] Rawalpindi Med Univ, Rawalpindi, Pakistan
[2] Univ Sch, Hunting Valley, OH USA
[3] Faisalabad Med Univ, Faisalabad, Pakistan
[4] Univ Arizona, Tucson, AZ USA
[5] Shifa Int Hosp Ltd, Islamabad, Pakistan
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187691
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis
    Jiao, Ning
    Shi, Lina
    Wang, Shaohua
    Sun, Yonghao
    Bai, Yujun
    Zhang, Dengshan
    BMC CANCER, 2024, 24 (01)
  • [42] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
    DiNardo, C. D.
    Jonas, B. A.
    Pullarkat, V.
    Thirman, M. J.
    Garcia, J. S.
    Wei, A. H.
    Konopleva, M.
    Doehner, H.
    Letai, A.
    Fenaux, P.
    Koller, E.
    Havelange, V.
    Leber, B.
    Esteve, J.
    Wang, J.
    Pejsa, V.
    Hajek, R.
    Porkka, K.
    Illes, A.
    Lavie, D.
    Lemoli, R. M.
    Yamamoto, K.
    Yoon, S. -S.
    Jang, J. -H.
    Yeh, S. -P.
    Turgut, M.
    Hong, W. -J.
    Zhou, Y.
    Potluri, J.
    Pratz, K. W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07): : 617 - 629
  • [43] The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study
    Yu, Guopan
    Yao, Zurong
    Yin, Zhao
    Zhang, Yu
    Zhao, Weihua
    Weng, Guangyang
    Guo, Ziwen
    Sun, Zhiqiang
    Shi, Pengcheng
    Jiang, Xuejie
    Xu, Dan
    Xuan, Li
    Liu, Qifa
    BLOOD, 2024, 144 : 4283 - 4283
  • [44] Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia
    Bouligny, Ian M.
    Murray, Graeme
    Ho, Thuy
    Doyel, Michael
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Alnimer, Yanal
    Zacholski, Kyle
    Venn, Chad
    Wages, Nolan A.
    Grant, Steven
    Maher, Keri R.
    LEUKEMIA RESEARCH, 2023, 134
  • [45] Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
    Richard-Carpentier, Guillaume
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [46] VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IMPROVE THE REMISSION RATE IN OLDER OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
    Han, Xiao
    Song, Qingxiao
    Wan, Kai
    Zhang, Mengyun
    Liu, Xue
    Yan, Hongju
    Zhang, Cheng
    Wen, Qin
    Zhang, Xi
    BONE MARROW TRANSPLANTATION, 2024, 59 : 176 - 177
  • [47] Venetoclax in Combination with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Is Comparable to Alternative Regimens
    Miller, Jenn
    Shannon, Lindsey
    Finch, Amanda
    Altman, Jessica K.
    Wojenski, Daniel
    BLOOD, 2020, 136
  • [48] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [49] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
  • [50] Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
    Gutman, Jonathan A.
    Winters, Amanda
    Kent, Andrew
    Amaya, Maria
    Mcmahon, Christine
    Smith, Clayton
    Jordan, Craig T.
    Stevens, Brett
    Minhajuddin, Mohammad
    Pei, Shanshan
    Schowinsky, Jeffrey
    Tobin, Jennifer
    O'Brien, Kelly
    Falco, Angela
    Taylor, Elizabeth
    Brecl, Constance
    Zhou, Katie
    Ho, Phuong
    Sohalski, Connor
    Dell-Martin, Jessica
    Ondracek, Olivia
    Abbott, Diana
    Pollyea, Daniel A.
    HAEMATOLOGICA, 2023, 108 (10) : 2616 - 2625
12345